In our study, SLC38A2 was identified as a risk factor in BRCA, LUAD, MESO, and PAAD, where its high expression is associated with poor prognosis and shorter survival, aligning with other research findings (Morotti et al., 2021; Liu et al., 2022; Li et al., 2023a; Morotti et al., 2019). This evidence concerns the gene SLC38A2 and pancreatic adenocarcinoma.